The addition of ZNLabs expands Zoetis’ reference laboratory capabilities in the U.S.
PARSIPPANY, N.J. & TAMPA, Fla.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S. This follows Zoetis’ recent acquisition of Phoenix Lab as its entry into reference laboratory services and builds on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians in the U.S. Financial terms of the transaction are not being disclosed.
Founded by veterinarians seeking to revolutionize reference laboratory services for companion animals, ZNLabs is guided by its mission to be “Simple. Friendly. Fair.” The company has differentiated itself by offering a simple test menu and fast results with friendly service and no contracts. ZNLabs operates a “hub” laboratory in Louisville, adjacent to a major logistics provider for fast sample turnaround times, with its “spoke” laboratories in Boise, Chicago, Cincinnati, Dallas, New Orleans and Salt Lake City providing local service in key U.S. markets.
Acquisition Strengthens Zoetis’ Position in Reference Labs
“The addition of ZNLabs strengthens our portfolio, expands our diagnostics footprint and enhances our value proposition to veterinary customers. Together with ZNLabs – and the recently added team from Phoenix Lab with over 30 years of trusted reference lab experience – we will focus on integrated solutions across the continuum of animal care,” said Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy for Zoetis. “We plan to grow further in this space through a mixture of small, business development activities combined with organic expansions in key markets in the coming years.”
“We built ZNLabs with the dream of providing a national reference lab that truly partners with clients and makes testing more accessible for pet owners with our simple, fair pricing model,” said David W. Gardiner, DVM, DACVP, co-founder, co-Chief Medical Officer and Chief Pathology Officer, ZNLabs. “Now with Zoetis, we will be able to rapidly continue to build our innovative reference lab model and provide an expanded diagnostic testing solution to more clients than we ever could have done by ourselves. In my entire career, I’ve never been more excited about the future of veterinary diagnostics.”
“Thanks to the extraordinary efforts of our small team – our ‘Zennies’ – we have in a relatively short time provided the veterinary community with a friendly, high-quality and trusted alternative to existing commercial laboratory services,” said Andrew Loar, DVM, DACVIM (IM & Oncology), co-founder and co-Chief Medical Officer, ZNLabs. “For our next phase, we are pleased to join Zoetis as they fuel ZNLabs’
humble, ambitious beginnings into a formidable presence in the veterinary laboratory space.”
“For me as a clinician, and speaking for ZNLabs’
founders, clinical veterinary medicine will thrive so long as the tools we use – particularly laboratory testing – remain accessible to us and appealing to pet owners,” continued Dr. Loar. “As part of Zoetis, we can scale our ‘simple, friendly and fair’ model and grow a nationwide network of excellent laboratory facilities.”
Reference Labs Complement Point-of-Care Diagnostics
Reference laboratories and point-of-care diagnostic testing are highly synergistic, offering veterinarians a single source for a full spectrum of tests, as well as access to the expertise of Board-certified specialists and pathologists to support test results. In 2018, through the acquisition of Abaxis, Inc., and its world-class portfolio of VetScan® diagnostic instruments and rapid tests, Zoetis became a leader in the development, manufacture, and marketing of veterinary point-of-care diagnostic instruments and consumables.
The global veterinary diagnostics category, which includes reference laboratory and point-of-care diagnostics, is estimated to be $4 billion1, with compound annual growth of approximately 10% over the past three years1. Zoetis expects the diagnostics category to continue to grow faster than the animal health industry, with growth in the mid to high single digits; this growth is driven by international adoption of point-of-care diagnostic instruments due to pet owners’ increasing interest in pet wellness trends, rising medicalization rates, increasing standards of veterinary care and the convenience of in-clinic testing1.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com.
About ZNLabs
ZNLabs is an innovative, full-service national veterinary diagnostic reference laboratory focused on revolutionizing the reference laboratory space for companion animals. With its team of friendly, motivated and highly collaborative business and veterinary professionals, ZNLabs stands for “Simple. Friendly. Fair.” ZNLabs has its hub laboratory in Louisville and regional laboratories in Boise, Chicago, Cincinnati, Dallas, New Orleans and Salt Lake City, with key management activities based in Tampa, Fla. For more information, visit www.znlabs.com.
Forward-Looking Information
This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, expectations regarding the performance of acquired companies and our ability to integrate new businesses, expectations regarding the financial impact of acquisitions, future use of cash and dividend payments, and other future events.
These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
1 Based on internal estimates and publicly available information.
Zoetis Media:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com
Christina Lood
1-973-822-7249 (o)
christina.lood@zoetis.com
Zoetis Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com
ZNLabs:
Dana Paris
1-813-819-0444 (o)
dana@znlabs.com